The U.S. Food and Drug Administration on Wednesday approved a second oral GLP-1 medication, giving adults eligible for weight ...
Under the new priority voucher program (CNPV), the FDA has approved a new oral GLP-1 drug, Foundayo, offering an alternative ...
ATTAIN demonstrated placebo-adjusted weight reductions of roughly 9–11 percentage points at 72 weeks, with 27.3 lb (12.4%) mean loss in adherent highest-dose recipients.
FDA approved the Eli Lilly’s daily weight‑loss pill, a fast‑tracked GLP‑1 drug offering a new option for obesity treatment.
A doctor discusses common issues and questions around Foundayo, the oral obesity pill approved by the FDA this week.
Eli Lilly's new daily pill GLP-1 moved through the FDA approval process faster after the FDA's new review and approval process.
Wegovy pill, the first FDA‑approved oral GLP‑1 for weight loss, is now available via WeightWatchers Med+ from $149 per month ...
At the heart of the request is whether taking Foundayo - made with a new active ingredient called orforglipron - could be ...
The state Senate passed a bill Friday regulating copycat versions of popular weight loss drugs like Ozempic and Wegovy.
A new daily pill, called Foundayo, is the second oral GLP-1 to reach the market in recent months, following the FDA approval of Novo Nordisk’s Wegovy pill.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results